Nematodes

Nematodes, also known as roundworms, constitute a vast phylum of elongated, non-segmented worms that are ubiquitous in diverse environments [11, 12]. While many are free-living, many species are significant human pathogens responsible for debilitating diseases such as ascariasis, hookworm infection, and lymphatic filariasis [3, 11]. Within the context of drug discovery, 'Nematodes' is not a single molecular target or receptor but rather the pathogen group toward which anthelmintic therapies are directed [1, 4]. These drugs exert their clinical effects by binding to specific molecular targets inside the worm, including glutamate-gated chloride channels (targeted by ivermectin), nicotinic acetylcholine receptors (targeted by levamisole), and beta-tubulin subunits (targeted by benzimidazoles) [4, 6]. Selective toxicity is typically achieved by targeting proteins that are either unique to nematodes or have significantly different pharmacological profiles compared to their human homologs [4, 8]. The phylum includes important model organisms like Caenorhabditis elegans, which is used extensively to identify and validate new molecular targets for treatment [1, 14]. Increasing global drug resistance in nematode populations remains a major therapeutic challenge, necessitating the ongoing discovery of novel biochemical 'chokepoints' and receptors within the phylum [2, 5].

Other names

RoundwormsPhylum NematodaEelwormsThreadworms

Anthelmintic drugs disrupt the parasite's physiological processes by targeting specific molecular sites such as glutamate-gated chloride channels, nicotinic acetylcholine receptors, and beta-tubulin, leading to paralysis or metabolic failure.